Defining the Role of the Skin Microbiome in Immune-related Adverse Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

175 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for metastatic melanoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

NCT06154668

Melanoma

RECRUITING

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

NCT07050940

Melanoma Metastatic

RECRUITING NA

LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

NCT06623461

Melanoma

RECRUITING PHASE2

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391

Melanoma

ACTIVE_NOT_RECRUITING PHASE1

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

NCT05649683

Melanoma (Skin)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Melanoma is the most dangerous skin cancer accounting for the highest skin cancer deaths. The prognosis for metastatic melanoma has improved considerably in recent years thanks to advances in the field of immunotherapy. The development of molecules blocking certain immunological "checkpoints" (checkpoints exerted by the CTLA-4 (Cytotoxic T lymphocytes Associated protein 4) and PD-1 (Programmed cell Death protein 1) has made it possible to obtain a significant improvement of the overall survival (OS) of patients treated for metastatic melanoma. Ipilimumab, an antibody blocking CTLA-4, is the first immunotherapy marketed, demonstrating for the first time a therapeutic response, however in a small number of patients (10 to 15%) and with significant toxicity (25% of grade 3-4). Subsequently, a second generation of more effective checkpoint blockers (30 to 40% good response) and less toxic, anti-PD-1 antibodies (pembrolizumab and nivolumab), quickly obtained a marketing authorization in the first line treatment of metastatic melanoma treatment and recently in an adjuvant situation after lymph node dissection in order to limit the risk of recurrence. However, despite these advances, a certain number of patients do not respond to treatment and it remains difficult to predict this therapeutic response. Furthermore, patients treated with ICI often experience cutaneous immune-related adverse events manifesting as skin rash, dermatitis, epidermal necrolysis, and in some cases as vitiligo like depigmentation of the skin, testifying to the development of a specific immunogenicity towards the melanocytes, cells causing melanoma, and responsible for a discoloration of the skin. Several studies have reported that a modification of certain bacteria in the digestive microbiota was predictive of the antitumor response to immunotherapy, while others were predictive of the appearance of significant autoimmune ICI-related toxicities (colitis). Several phase 1 studies have evaluated the impact of taking probiotics or fecal transplants on the tumor response of patients receiving immunotherapy for cancer (NCT 03819296; NCT03817125; NCT03643289). Thus by these new concepts, it would be interesting to assess the composition of the skin microbiota in patients treated with anti-PD-1 immunotherapy for the management of metastatic melanoma and developing during their follow-up vitiligo; predictive side effect of improved survival. These data will be compared to those obtained from patients with common vitiligo. This will be examined in patients skin swabs sampled at lesional and non-lesional sites. Functionally, we will characterize the microbial pathways using shotgun sequencing of microbial genomes and meta-transcriptomics (RNA sequencing of microbial communities of the skin).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo Skin Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Prospective, Monocentric (CHU de Bordeaux, Department of dermatology ), with 4 groups :

* vitiligo patients
* Metastatic melanoma patients receiving anti-PD-1 but without cutaneous irAEs
* Metastatic melanoma patients receiving anti-PD-1 who developed vitiligo lesions
* metastatic melanoma patients who developed vitiligo under anti-PD-1, who discontinued the treatment.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitiligo patients

Adult patients diagnosed with Vitiligo according to usual criteria

Group Type EXPERIMENTAL

skin swabs at lesional and non-lesional sites

Intervention Type PROCEDURE

It will be examined in patients skin swabs sampled at lesional and non-lesional sites

metastatic melanoma patients under anti-PD-1 who did not develop cutaneous irAEs

metastatic melanoma patients under anti-PD-1 who did not develop Cutaneous Immune-Related Adverse Events (cutaneous irAEs).

Group Type EXPERIMENTAL

skin swabs on skin

Intervention Type PROCEDURE

It will be examined in patients skin swabs sampled on skin

Metastatic melanoma patients under anti-PD-1 who developed vitiligo lesions

patients with metastatic melanoma, under anti-PD-1 who developed vitiligo lesions

Group Type EXPERIMENTAL

skin swabs at lesional and non-lesional sites

Intervention Type PROCEDURE

It will be examined in patients skin swabs sampled at lesional and non-lesional sites

metastatic melanoma patients with vitiligo lesions under anti-PD-1 who discontinued

Metastatic melanoma who developed vitiligo lesions under anti-PD-1 who discontinued the treatment

Group Type EXPERIMENTAL

skin swabs at lesional and non-lesional sites

Intervention Type PROCEDURE

It will be examined in patients skin swabs sampled at lesional and non-lesional sites

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

skin swabs at lesional and non-lesional sites

It will be examined in patients skin swabs sampled at lesional and non-lesional sites

Intervention Type PROCEDURE

skin swabs on skin

It will be examined in patients skin swabs sampled on skin

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients diagnosed with Vitiligo according to usual criteria.
* Adult patients with metastatic melanoma, under anti-PD-1 who developed vitiligo
* Adult patients with metastatic melanoma who did not develop Immune related adverse events under anti-PD-1
* Adult patients with metastatic melanoma who developed vitiligo under anti-PD-1 and discontinued the treatment
* Free, informed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria

* Patients under 18 years old.
* No treatment for vitiligo in the past 4 weeks
* Patients under legal protection or unable to express their consent.
* Patients not affiliated to a health insurance system.
* Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No